PolyNovo Limited

ASX PNV.AX

PolyNovo Limited Market Capitalization on January 14, 2025: USD 904.60 M

PolyNovo Limited Market Capitalization is USD 904.60 M on January 14, 2025, a 29.34% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • PolyNovo Limited 52-week high Market Capitalization is USD 1.26 B on September 26, 2024, which is 39.55% above the current Market Capitalization.
  • PolyNovo Limited 52-week low Market Capitalization is USD 691.35 M on January 16, 2024, which is -23.57% below the current Market Capitalization.
  • PolyNovo Limited average Market Capitalization for the last 52 weeks is USD 1.01 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
ASX: PNV.AX

PolyNovo Limited

CEO Mr. Swami Raote BPHARM, M.B.A.
IPO Date Nov. 30, 1998
Location Australia
Headquarters 320 Lorimer Street
Employees 254
Sector Health Care
Industries
Description

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Similar companies

PME.AX

Pro Medicus Limited

USD 157.25

0.24%

MP1.AX

Megaport Limited

USD 4.12

1.00%

NAN.AX

Nanosonics Limited

USD 2.01

-0.68%

StockViz Staff

January 15, 2025

Any question? Send us an email